## Amendments to the Claims:

1. (Original) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms and a pharmaceutically acceptable excipient.

## Claims 2-12. (Cancelled)

13. (Previously Presented) A pharmaceutical composition in accordance with claim 1, wherein said compound has the formula:

where: L and L' are ligands; R' and R" are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 to 3; b is 0 to 3; R" is H,  $SO_3$ ,  $PO_4^{2-}$ ,  $CO_2H$ , OH,  $(CH_2)_nCH_3$ , O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, S(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, or NR""C(O)(R"") where R"" and R"" are (CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>; and n is 0 to 6.

14. (Original) A pharmaceutical composition in accordance with claim 13, wherein said compound has a formula selected from the group consisting of:

Claims 15-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition in accordance with claim 13, wherein L and L' are independently selected from the group consisting of PR<sub>3</sub>, P(OR)<sub>3</sub>, CNR, NCR, PR<sub>n</sub>(CH<sub>2</sub>OR<sup>‡</sup>)<sub>3-n</sub>, N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>, [N<sub>4</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, PN<sub>3</sub>C<sub>6</sub>H<sub>12</sub>, and P[N<sub>3</sub>C<sub>6</sub>H<sub>12</sub>-N-CH<sub>3</sub>]<sup>+</sup>, where R is a substituted or unsubstituted hydrocarbon moiety and R<sup>‡</sup> is selected from the group consisting of H, Me, SO<sub>2</sub><sup>-</sup>, PO<sub>3</sub><sup>-</sup>, alkyl and aryl, and each R<sup>‡</sup> in any one ligand is the same or different.

- 21. (Original) A pharmaceutical composition in accordance with claim 20, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.
- 22. (Previously Presented) A pharmaceutical composition in accordance with claim 20, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.
- 23. (Previously Presented) A pharmaceutical composition in accordance with claim 20, wherein the ligand is PPh<sub>3</sub>.
- 24. (Previously Presented) A pharmaceutical composition in accordance with claim 13, wherein R' and R" are each independently selected from the group consisting of methylene, ethylene, propylene, butylene and phenylene groups.

Claims 25-40. (Cancelled).